2 - TI Pharma
2 - TI Pharma 2 - TI Pharma
Chapter 8 Glucocorticoids affect intermediary metabolism Supplementary Table 1. Parameters of body composition and body fat distribution before and during two-week treatment with placebo, prednisolone 7.5 mg or prednisolone 30 mg. BMI (kg/m2 ) LBM (%) Fat mass (%) Liver fat content (%) SAT area (cm2 ) VAT area (cm2 ) 172 Pre-treatment On-treatment P PLB 23.0±2.3 22.8±2.2 7.5 22.3±2.0 22.3±1.8 0.449 30 22.6±1.1 22.6±1.1 PLB 78.6±7.9 80.2±10.0 7.5 82.1±3.9 81.8±3.7 0.275 30 80.7±2.5 80.9±2.0 PLB 16.9±4.7 17.1±4.6 7.5 15.9±2.8 16.1±3.7 0.503 30 14.8±3.5 14.7±3.2 PLB 1.3 (0.3-2.5) 1.5 (0.4-3.5) 7.5 0.8 (0.4-2.1) 1.3 (0.7-2.4) 0.537 30 1.0 (0.5-1.6) 1.6 (1-1.8) PLB 131 (91-202) 130 (102-201) 7.5 127 (94-154) 130 (89-160) 0.447 30 129 (114-151) 132 (114-147) PLB 82 (48-107) 71 (48-112) 7.5 72 (69-99) 86 (66-93) 0.291 30 77 (67-88) 80 (72-88) Mean±SD or median (interquartile range) are provided. Between-group changes from baseline were tested by Kruskal-Wallis (P). No significnant differences were observed during treatment. Abbreviations: BMI: body mass index; LBM: lean body mass; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue. Treatment groups: PLB=placebo; 7.5=prednisolone 7.5 mg daily; 30=prednisolone 30 mg daily.
- Page 294: SUPPLEMENTAL FIGURES Supplemental F
- Page 302: Chapter 8 Low-dose Glucocorticoid T
- Page 306: Glucocorticoids (GCs) are the corne
- Page 310: Experimental protocol - clamp: Afte
- Page 314: Statistics: Data are presented as m
- Page 318: Lipid Metabolism: Lipolysis in the
- Page 322: Figure 3. The effect of prednisolon
- Page 326: By including an additional treatmen
- Page 330: treating patients with GC therapy.
- Page 334: 16. Hoes jN, jacobs jW, Verstappen
- Page 338: 44. Schakman O, Gilson H, Thissen j
- Page 342: Supplementary Figure 3. Kinetic equ
- Page 350: Chapter 9 Glycosphingolipid Metabol
- Page 354: INTRoDUCTIoN Glucocorticoids (GCs)
- Page 358: Experimental protocol: The design o
- Page 362: oxidative phosphorylation (OXPHOS)
- Page 366: Table 3. Mitochondrial respiration
Chapter 8 Glucocorticoids affect intermediary metabolism<br />
Supplementary Table 1. Parameters of body composition and body fat distribution before and during<br />
two-week treatment with placebo, prednisolone 7.5 mg or prednisolone 30 mg.<br />
BMI<br />
(kg/m2 )<br />
LBM<br />
(%)<br />
Fat mass<br />
(%)<br />
Liver fat content<br />
(%)<br />
SAT area<br />
(cm2 )<br />
VAT area<br />
(cm2 )<br />
172<br />
Pre-treatment On-treatment P<br />
PLB 23.0±2.3 22.8±2.2<br />
7.5 22.3±2.0 22.3±1.8<br />
0.449<br />
30 22.6±1.1 22.6±1.1<br />
PLB 78.6±7.9 80.2±10.0<br />
7.5 82.1±3.9 81.8±3.7<br />
0.275<br />
30 80.7±2.5 80.9±2.0<br />
PLB 16.9±4.7 17.1±4.6<br />
7.5 15.9±2.8 16.1±3.7<br />
0.503<br />
30 14.8±3.5 14.7±3.2<br />
PLB 1.3 (0.3-2.5) 1.5 (0.4-3.5)<br />
7.5 0.8 (0.4-2.1) 1.3 (0.7-2.4)<br />
0.537<br />
30 1.0 (0.5-1.6) 1.6 (1-1.8)<br />
PLB 131 (91-202) 130 (102-201)<br />
7.5 127 (94-154) 130 (89-160)<br />
0.447<br />
30 129 (114-151) 132 (114-147)<br />
PLB 82 (48-107) 71 (48-112)<br />
7.5 72 (69-99) 86 (66-93)<br />
0.291<br />
30 77 (67-88) 80 (72-88)<br />
Mean±SD or median (interquartile range) are provided. Between-group changes from baseline were<br />
tested by Kruskal-Wallis (P). No significnant differences were observed during treatment. Abbreviations:<br />
BMI: body mass index; LBM: lean body mass; SAT: subcutaneous adipose tissue; VAT: visceral adipose<br />
tissue. Treatment groups: PLB=placebo; 7.5=prednisolone 7.5 mg daily; 30=prednisolone 30 mg daily.
Change language